Compare JYNT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | RPID |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | 330 | N/A |
| Industry | Multi-Sector Companies | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.7M | 84.8M |
| IPO Year | 2014 | 2021 |
| Metric | JYNT | RPID |
|---|---|---|
| Price | $7.00 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $10.00 | $5.75 |
| AVG Volume (30 Days) | 80.2K | ★ 322.0K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | 2.78 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $117,696,356.00 | $33,587,000.00 |
| Revenue This Year | $10.93 | $16.95 |
| Revenue Next Year | $2.78 | $17.92 |
| P/E Ratio | $50.86 | ★ N/A |
| Revenue Growth | 15.49 | ★ 19.74 |
| 52 Week Low | $6.99 | $0.83 |
| 52 Week High | $10.67 | $4.94 |
| Indicator | JYNT | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 26.76 | 26.70 |
| Support Level | N/A | N/A |
| Resistance Level | $9.46 | $2.18 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 2.44 | 22.28 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.